Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Internal Medicine
•
Hematology
•
Sickle Cell
•
Benign Hematology
Would you start a patient with sickle cell disease and COVID-19 on prophylactic anticoagulation?
Related Questions
How would you approach secondary stroke prevention in an adult with Hemoglobin SC disease?
What subset of sickle cell disease patients are you offering sickle cell disease gene therapy?
Is there any indication for hydroxyurea in patients with sickle cell trait?
Would you consider continuing or re-trialing hydroxyurea for sickle cell patients after development of a leg ulcer?
How do you counsel sickle cell patients on the use of G-CSF to treat neutropenia from other causes, like malignancy?
For mild to moderate hemophilia B, do you routinely screen for inhibitors?
What is your strategy for optimizing hydroxyurea dosage in patients with symptomatic sickle cell disease, particularly for genotypes HbSS and HbS/Beta thal?
What would you recommend for long term management of extensive dural venous sinus thrombosis (CVST) in young females when the only provoking risk factor is combined OCP?
Is there any benefit of using aspirin to mitigate VTE risk in testosterone-induced polycythemia?
How do you manage arthritis resulting from deferiprone in transfusion dependent thalassemia?
